The episode where Mayo Clinic & Anumana transform ECG with AI; ConcertAI dishes on next-gen trials

Welcome to DeviceTalks AI, a DeviceTalks podcast offering a comprehensive look into the intersection of AI and the medical device industry from two unique perspectives. In the first segment, Paul Friedman, MD, Chair of the Department of Cardiovascular Medicine at Mayo Clinic, and Dave McMullin, Chief Business Officer of Anumana, discuss the groundbreaking collaboration between Mayo Clinic and Anumana in applying AI to enhance cardiovascular diagnostics, particularly through ECGs. They explore how AI can detect cardiac conditions early, with a focus on the EAGLE study's findings on AI-enhanced ECGs, and discuss Anumana's role in transforming these AI innovations into accessible medical devices. In the second segment, Jeff Elton, PhD, CEO of ConcertAI, speaks to the transformative role of AI in clinical trials. He sheds light on AI's capabilities in improving patient selection for clinical trials and streamlining processes within life sciences. Dr. Elton emphasizes the broader implications of AI, from enhancing patient care to accelerating the development of new treatments, and discusses the ethical considerations of AI integration in healthcare.These interviews provide insights into the evolving roles of AI in various sectors like medtech, pharma, and biotech, showcasing its potential in transforming healthcare and research methodologies. But that's not all! Join us for the next episode of DeviceTalks AI, which features an interview with the Global Business Leader for Health and Life Sciences at Microsoft. Catch the full episode on all major podcast platforms and the DeviceTalks YouTube to dive deeper into the exciting convergence of AI and medtech. Thank you to our contributors, some of who include Catalyze Healthcare and SmartTRAK Business Intelligence, for providing vital support. To learn more about our contributors, visit: www.catalyzehealthcare.com and www.smarttrak.com. Thank you for listening to DeviceTalks AI.